{
    "ticker": "IGMS",
    "name": "IGM Biosciences, Inc.",
    "description": "IGM Biosciences, Inc. is a biotechnology company focused on the discovery and development of innovative monoclonal antibody therapies for the treatment of cancer and autoimmune diseases. Founded in 2010 and based in Mountain View, California, IGM aims to harness the power of immunotherapy to create more effective and safer treatments for patients. The company's proprietary IGM antibody platform enables the design of next-generation antibodies with enhanced potency and specificity. IGM's lead product candidates include IGM-2323, a bispecific antibody targeting CD20 and CD3, which is currently in clinical trials for treating hematological malignancies. The company is also exploring additional pipeline candidates that leverage its unique platform technology to address unmet medical needs in oncology. IGM Biosciences is committed to advancing science and improving patient outcomes through its innovative therapies and strategic collaborations with leading research institutions and pharmaceutical companies. With a robust pipeline and a strong intellectual property position, IGM is well-positioned to make significant contributions to the field of antibody-based therapies.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Mountain View, California, USA",
    "founded": "2010",
    "website": "https://www.igmbio.com",
    "ceo": "Fred Schwarzer",
    "social_media": {
        "twitter": "https://twitter.com/igmbiosciences",
        "linkedin": "https://www.linkedin.com/company/igm-biosciences"
    },
    "investor_relations": "https://investors.igmbio.com",
    "key_executives": [
        {
            "name": "Fred Schwarzer",
            "position": "CEO"
        },
        {
            "name": "Robert J. Dorr",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "IGM-2323"
            ]
        }
    ],
    "seo": {
        "meta_title": "IGM Biosciences, Inc. | Innovative Monoclonal Antibody Therapies",
        "meta_description": "IGM Biosciences, Inc. focuses on developing innovative monoclonal antibody therapies for cancer and autoimmune diseases. Learn more about our pipeline and technology.",
        "keywords": [
            "IGM Biosciences",
            "Biotechnology",
            "Monoclonal Antibodies",
            "Cancer Treatment",
            "Autoimmune Diseases"
        ]
    },
    "faq": [
        {
            "question": "What does IGM Biosciences specialize in?",
            "answer": "IGM Biosciences specializes in developing innovative monoclonal antibody therapies for cancer and autoimmune diseases."
        },
        {
            "question": "Who is the CEO of IGM Biosciences?",
            "answer": "Fred Schwarzer is the CEO of IGM Biosciences, Inc."
        },
        {
            "question": "Where is IGM Biosciences headquartered?",
            "answer": "IGM Biosciences is headquartered in Mountain View, California, USA."
        },
        {
            "question": "What is IGM's lead product candidate?",
            "answer": "IGM's lead product candidate is IGM-2323, which targets CD20 and CD3 for hematological malignancies."
        },
        {
            "question": "When was IGM Biosciences founded?",
            "answer": "IGM Biosciences was founded in 2010."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "BMY",
        "VRTX"
    ],
    "related_stocks": [
        "GILD",
        "MRNA",
        "NVAX",
        "PFE"
    ]
}